US20230041584A1 - Novel prodrugs and conjugates of dimethyltryptamine - Google Patents

Novel prodrugs and conjugates of dimethyltryptamine Download PDF

Info

Publication number
US20230041584A1
US20230041584A1 US17/836,984 US202217836984A US2023041584A1 US 20230041584 A1 US20230041584 A1 US 20230041584A1 US 202217836984 A US202217836984 A US 202217836984A US 2023041584 A1 US2023041584 A1 US 2023041584A1
Authority
US
United States
Prior art keywords
compound
alkyl
hydrogen
formula
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/836,984
Other languages
English (en)
Inventor
Robert B. Perni
Glenn Short
Srinivas G. Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Life Sciences US Inc
Atai Therapeutics Inc
Viridia Life Sciences Inc
Original Assignee
Atai Life Sciences AG
JMD Pharma Creativity LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Life Sciences AG, JMD Pharma Creativity LLC filed Critical Atai Life Sciences AG
Priority to US17/836,984 priority Critical patent/US20230041584A1/en
Priority to US17/889,013 priority patent/US11643391B2/en
Assigned to JMD PHARMA CREATIVITY, LLC reassignment JMD PHARMA CREATIVITY, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERNI, ROBERT B.
Assigned to ATAI Life Sciences AG reassignment ATAI Life Sciences AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHAN, TANWEER A., RAO, SRINIVAS G., SHORT, GLENN
Publication of US20230041584A1 publication Critical patent/US20230041584A1/en
Priority to US18/299,347 priority patent/US12065405B2/en
Assigned to ATAI LIFE SCIENCES US, INC. reassignment ATAI LIFE SCIENCES US, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JMD PHARMA CREATIVITY, LLC
Assigned to ATAI Life Sciences AG reassignment ATAI Life Sciences AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATAI LIFE SCIENCES US, INC.
Assigned to VIRIDIA LIFE SCIENCES, INC. reassignment VIRIDIA LIFE SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATAI Life Sciences AG
Assigned to ATAI THERAPEUTICS, INC. reassignment ATAI THERAPEUTICS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: VIRIDIA LIFE SCIENCES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Definitions

  • N,N-dimethyltryptamine is a naturally occurring compound found in numerous plant species and botanical preparations, such as the hallucinogenic infusion known as ayahuasca, and classified as a classic serotonergic psychedelic that induces intense modifications in perception, emotion, and cognition in humans.
  • DMT has a rapid onset, intense psychedelic effects, and a relatively short duration of action with an estimated half-life of less than fifteen minutes.
  • DMT binds to serotonin receptors to produce euphoria and psychedelic effects.
  • DMT is metabolically unstable and is readily converted by monoamine oxidases (MAO's) to indoleacetic acid and N-oxidation metabolites resulting in poor oral bioavailability.
  • MAO's monoamine oxidases
  • Serotonergic psychedelics have also demonstrated promising antidepressant, anxiolytic, and anti-addictive properties.
  • DMT N,N-dimethyltryptamine
  • the present disclosure provides a compound of Formula (I):
  • the compound of Formula (I) is a compound of the Formula (IV):
  • the compound of Formula (I) is a compound of the formula:
  • the present disclosure provides a compound of Formula (III):
  • the compound of Formula (V) is a compound of the formula:
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • FIG. 1 shows PK studies of N-phosphonooxymethyl prodrug 6-1-2 (VLS-02-23-0) and metabolite (VLS-02-023-10) following intravenous (1 mg/kg) and oral administration (30 mg/kg) to male CD1 mice (in plasma).
  • FIG. 2 shows PK studies of N-phosphonooxymethyl prodrug 6-1-2 (VLS-02-23-0) and metabolite (VLS-02-023-10) following intravenous (1 mg/kg) and oral administration (30 mg/kg) to male CD1 mice (in the brain).
  • the term “about” when immediately preceding a numerical value means a range (e.g., plus or minus 10% of that value).
  • “about 50” can mean 45 to 55
  • “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation.
  • “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 50.5.
  • the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein.
  • the term “about” when preceding a series of numerical values or a range of values refers, respectively to all values in the series, or the endpoints of the range.
  • administer refers to administering a compound or pharmaceutically acceptable salt of the compound or a composition or formulation comprising the compound or pharmaceutically acceptable salt of the compound to a patient.
  • salts includes both acid and base addition salts.
  • Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p-toluenesulfonate salts.
  • non-toxic acid addition salts i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p-toluene
  • Base addition salts include but are not limited to, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris-(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine dicyclohexylamine and the like.
  • metal salts include lithium, sodium, potassium, magnesium, calcium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
  • organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like.
  • treating refers to improving at least one symptom of the patient's disorder.
  • treating can be improving, or at least partially ameliorating a disorder or one or more symptoms of a disorder.
  • preventing refers to preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject or a patient that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
  • terapéuticaally effective applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof.
  • C 1 -C 6 alkyl is intended to encompass C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 alkyl.
  • Alkyl or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C 1 -C 12 alkyl, an alkyl comprising up to 10 carbon atoms is a C 1 -C 10 alkyl, an alkyl comprising up to 6 carbon atoms is a C 1 -C 6 alkyl and an alkyl comprising up to 5 carbon atoms is a C 1 -C 5 alkyl.
  • a C 1 -C 5 alkyl includes C 5 alkyls, C 4 alkyls, C 3 alkyls, C 2 alkyls and C 1 alkyl (i.e., methyl).
  • a C 1 -C 6 alkyl includes all moieties described above for C 1 -C 5 alkyls but also includes C 6 alkyls.
  • a C 1 -C 10 alkyl includes all moieties described above for C 1 -C 5 alkyls and C 1 -C 6 alkyls, but also includes C 7 , C 8 , C 9 and C 10 alkyls.
  • a C 1 -C 12 alkyl includes all the foregoing moieties, but also includes C 11 and C 12 alkyls.
  • Non-limiting examples of C 1 -C 12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.
  • an alkyl group can be optionally substituted.
  • Aryl refers to a hydrocarbon ring system comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring, and which is attached to the rest of the molecule by a single bond.
  • the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems.
  • Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the “aryl” can be optionally substituted.
  • Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon consisting solely of carbon and hydrogen atoms, which can include fused, bridged, or spirocyclic ring systems, having from three to twenty carbon atoms (e.g., having from three to ten carbon atoms) and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
  • Heterocyclyl refers to a stable saturated, unsaturated, or aromatic 3- to 20-membered ring which consists of two to nineteen carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and which is attached to the rest of the molecule by a single bond.
  • Heterocyclyl or heterocyclic rings include heteroaryls, heterocyclylalkyls, heterocyclylalkenyls, and hetercyclylalkynyls.
  • the heterocyclyl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spirocyclic ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl can be partially or fully saturated.
  • heterocyclyl examples include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholin
  • Heteroaryl refers to a 5- to 20-membered ring system comprising hydrogen atoms, one to nineteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, and which is attached to the rest of the molecule by a single bond.
  • the heteroaryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl can be optionally oxidized; the nitrogen atom can be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furany
  • substituted means any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclyl, and/or heteroaryl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides
  • “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple-bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • substituted includes any of the above groups in which one or more hydrogen atoms are replaced with —NR g R h , —NR g C( ⁇ O)R h , —NR g C( ⁇ O)NR g R h , —NR g C(O)OR h , —NR g SO 2 R h , —OC( ⁇ O)NR g R h , —OR g , —SR g , —SOR g , —SO 2 R g , —OSO 2 R g , —SO 2 OR g , ⁇ NSO 2 R g , and —SO 2 NR g R h .
  • “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with —C( ⁇ O)R g , —C( ⁇ O)OR g , —C( ⁇ O)NR g R h , —CH 2 SO 2 R g , —CH 2 SO 2 NR g R h .
  • R g and R h are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
  • “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group.
  • each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
  • the present disclosure provides compounds that are prodrugs of tryptamines and relates scaffolds, for example N,N-dimethyltryptamine (DMT) as well as pharmaceutical compositions thereof.
  • DMT N,N-dimethyltryptamine
  • DMT is metabolically unstable and is readily converted by monoamine oxidases (MAO's) to indoleacetic acid and N-oxidation metabolites resulting in poor oral bioavailability.
  • MAO's monoamine oxidases
  • the compounds of the present disclosure allow for the controlled release of DMT.
  • Advantages of compounds of the present disclosure may include increased metabolic stability, increased absorption, decreased maximal plasma concentrations of parent drug DMT over time, and less frequent dosing.
  • compounds of the present disclosure prevent or inhibit N-oxidation to promote oral bioavailability and increased exposure.
  • compounds of the present disclosure comprise an enacarbil moiety.
  • such compounds may for example, increase bioavailability by virtue of active transport of the prodrug in the small intestine by high-capacity nutrient transporters, including mono-carboxylate transporter-1 (MCT-1).
  • MCT-1 mono-carboxylate transporter-1
  • DMT-enacarbil prodrugs may also reduce abuse potential by preventing absorption by snorting or insufflation.
  • the present disclosure provides a compound of Formula (I):
  • R 9 is a halogen. In some embodiments, R 9 is bromo.
  • R 1 and R 2 are independently hydrogen, alkyl, or cycloalkyl, or R 1 and R 2 together with the atoms to which they are attached form a heterocycle.
  • R 1 and R 2 are independently hydrogen, alkyl, or cycloalkyl.
  • R 1 and R 2 together with the atoms to which they are attached form a heterocycle.
  • R 1 and R 2 are independently hydrogen or C 1 -C 6 alkyl.
  • R 1 and R 2 are independently C 1 -C 6 alkyl.
  • R 1 and R 2 are independently methyl, ethyl, propyl, and isopropyl.
  • R 1 and R 2 are methyl.
  • X, Y and Z are independently hydrogen, halogen, —O—, —S—, —NR A —, —O(P ⁇ O)—OR A (—OR′), or —(P ⁇ O)—OR A (—OR′).
  • X, Y and Z are H.
  • two of X, Y and Z are hydrogen.
  • two of X, Y and Z are hydrogen and the non-hydrogen X, Y or Z is —O—, —S—, —NR A —, —O(P ⁇ O)—OR A (—OR′), or —(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • X and Y are hydrogen; and Z is —O—, —S—, —NR A —, —O(P ⁇ O)—OR A (—OR′), or —(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • X and Z are hydrogen; and Y is —O—, —S—, —NR A —, —O(P ⁇ O)—OR A (—OR′), or —(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • Y and Z are hydrogen; and X is —O—, —S—, —NR A —, —O(P ⁇ O)—OR A (—OR′), or —(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • At least one of X, Y, or Z is —O(P ⁇ O)—OR A (—OR′).
  • X is —O(P ⁇ O)—OR A (—OR′) and R 3 is absent.
  • Y is —O(P ⁇ O)—OR A (—OR′) and R 4 is absent.
  • Z is —O(P ⁇ O)—OR A (—OR′) and R 5 is absent.
  • R′ is hydrogen or alkyl.
  • R A is hydrogen or alkyl.
  • R′, R 3 , R 4 , R 5 and R 6 are independently absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R′, R 3 , R 4 , R 5 and R 6 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R′, R 3 , R 4 , and R 5 are independently absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R′, R 3 , R 4 , and R 5 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R′ is absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R′ is hydrogen or alkyl.
  • R 3 is:
  • R 4 is:
  • R 5 is:
  • R 6 is: —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • X, Y and Z are H; W is NR 6 ; and R 6 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • At least one of R′, R 3 , R 4 , R 5 and R 6 is —(C ⁇ O)(CH 2 ) n (NH 2 ) and n is 3.
  • At least one of R′, R 3 , R 4 , R 5 and R 6 is —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), and n is 4.
  • At least one of R′, R 3 , R 4 , R 5 and R 6 is —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 and n is 3.
  • At least one of R′, R 3 , R 4 , R 5 and R 6 is —(C ⁇ O)CH(NH)(CH 2 ) n (C ⁇ NH)—NH 2 and n is 2.
  • At least one of R′, R 3 , R 4 , R 5 and R 6 is
  • At least one of R′, R 3 , R 4 , and R 5 is —(C ⁇ O)(CH 2 ) n (NH 2 ) and n is 3.
  • At least one of R′, R 3 , R 4 , and R 5 is —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ) and n is 4.
  • At least one of R′, R 3 , R 4 , and R 5 is —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 and n is 3.
  • At least one of R′, R 3 , R 4 , and R 5 is —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 and n is 2.
  • At least one of R′, R 3 , R 4 , and R 5 is
  • L and M are independently alkyl or aryl.
  • L is alkyl and M is alkyl or aryl.
  • L is methyl or isopropyl and M is alkyl or aryl.
  • W is oxygen, sulfur or NR 6 ;
  • W is NR 6 and R 6 is hydrogen or alkyl.
  • R 7 , R 8 , and R 9 are independently hydrogen or alkyl.
  • R 8 , and R 9 are independently hydrogen or alkyl.
  • R 8 is hydrogen
  • R 8 is alkyl
  • R 8 is C 1 -C 6 alkyl.
  • R 9 is hydrogen, halogen, or alkyl.
  • R 9 is hydrogen
  • R 9 is alkyl
  • R 9 is C 1 -C 6 alkyl.
  • R 9 is halogen.
  • R 9 is —F, —Cl, —Br, or —I.
  • R 9 is —Cl, —Br, or —I.
  • R 9 is —Cl or —Br.
  • R 9 is —F.
  • R 9 is —Cl.
  • R 9 is —Br.
  • R 9 is —I.
  • R 7 and R 8 are independently hydrogen or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • R 8 is hydrogen or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • R 9 is hydrogen, halogen, or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • R 7 , R 8 and R 9 are independently hydrogen or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • R 8 and R 9 are independently hydrogen or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • n is an integer from 2-7 (i.e. 2, 3, 4, 5, 6, or 7). In some embodiments n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7.
  • m is an integer from 1-4 (i.e. 1, 2, 3, or 4). In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.
  • the compound is of Formula (IV):
  • R 10 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • A is a pharmaceutically acceptable anion
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , X, Y, Z, W, and m are defined herein.
  • the compound of Formula (I) is a compound of Formula (V):
  • R 10 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • A is a pharmaceutically acceptable anion
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , X, Y, Z, and m are defined herein.
  • the present disclosure provides compounds of Formula (VI):
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein,
  • X is carbon or nitrogen
  • W is carbon, oxygen, or nitrogen
  • Z is hydrogen, deuterium, or oxygen.
  • the compound of Formula (VII) is:
  • the compound of Formula (VI) or (VII) is:
  • the present disclosure provides compounds of Formula (VIII):
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 9 are as defined herein,
  • R 11 and R 12 are independently a pharmaceutically acceptable salt, hydrogen, deuterium, alkyl, substituted alkyl, cycloalkyl, or R 11 and R 12 together with the atoms to which they are attached form an alkyl, cycloalkyl, heterocycles and are ether, hemiaminal ketal and amino acid.
  • R 11 and R 12 together with the atoms to which they are attached form a heterocycle.
  • the pharmaceutically acceptable salt is Na + , K + , or NH 4 + .
  • R 1 and R 2 are each independently hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • X, Y and Z are each independently hydrogen, halogen, —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′), wherein R′ and R A is hydrogen or alkyl; R 3 , R 4 , R 5 and R 6 are each independently absent, hydrogen, or alkyl; R 7 and R 8 are each independently hydrogen or alkyl; R 9 is hydrogen, alkyl, or halogen; L and M are each independently alkyl or aryl; W is oxygen, sulfur or NR 6 ; n is an integer from 2-7; and m is an integer from 1-4,
  • R 1 and R 2 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • X, Y and Z are each independently hydrogen, halogen, —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′).
  • X, Y and Z are hydrogen.
  • two of X, Y and Z are hydrogen.
  • two of X, Y and Z are hydrogen and the non-hydrogen X, Y or Z is —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • X and Y are hydrogen; and Z is —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • X and Z are hydrogen; and Y is —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • Y and Z are hydrogen; and X is —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl.
  • At least one of X, Y, or Z is —O(P ⁇ O)—OR A (—OR′).
  • X is —O(P ⁇ O)—OR A (—OR′) and R 3 is absent.
  • Y is —O(P ⁇ O)—OR A (—OR′) and R 4 is absent.
  • Z is —O(P ⁇ O)—OR A (—OR′) and R 5 is absent.
  • R′ is hydrogen or alkyl
  • R A is hydrogen or alkyl.
  • R 1 and R 2 are each independently absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R 1 and R 2 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R 1 is absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R 1 is hydrogen or alkyl.
  • R 2 is absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R 2 is hydrogen or alkyl.
  • At least one of R 1 and R 2 is —(C ⁇ O)(CH 2 ) n (NH 2 ) and n is 3.
  • At least one of R 1 and R 2 is —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ) and n is 4.
  • At least one of R 1 and R 2 is —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 and n is 3.
  • At least one of R 1 and R 2 is —(C ⁇ O)CH(NH)(CH 2 ) n (C ⁇ NH)—NH 2 and n is 2.
  • At least one of R 1 and R 2 is —(C ⁇ O)-alkyl.
  • At least one of R 1 and R 2 is
  • At least one of R 1 and R 2 is —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 and n is 4.
  • At least one of R 1 and R 2 is —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH)(C ⁇ NH)—NH 2 and n is 3.
  • L and M are each independently alkyl or aryl.
  • L is alkyl and M is alkyl or aryl.
  • L is methyl or isopropyl and M is alkyl or aryl.
  • R 3 is hydrogen
  • R 3 is alkyl
  • R 3 is C 1 -C 6 alkyl.
  • R 3 is absent.
  • R 4 is hydrogen
  • R 4 is alkyl
  • R 4 is C 1 -C 6 alkyl.
  • R 4 is absent.
  • R 5 is hydrogen
  • R 5 is alkyl
  • R 5 is C 1 -C 6 alkyl.
  • R 5 is absent.
  • W is oxygen, sulfur or NR 6 .
  • W is NR 6 and R 6 is hydrogen or alkyl.
  • R 7 , R 8 , and R 9 are each independently hydrogen or alkyl.
  • R 8 is hydrogen
  • R 8 is alkyl
  • R 8 is C 1 -C 6 alkyl.
  • R 9 is hydrogen, halogen, or alkyl.
  • R 9 is hydrogen
  • R 9 is alkyl
  • R 9 is C 1 -C 6 alkyl.
  • R 9 is halogen. In some embodiments, R 9 is —F, —Cl, —Br, or —I. In some embodiments, R 9 is —Cl, —Br, or —I. In some embodiments, R 9 is —Cl or —Br. In some embodiments, R 9 is —F. In some embodiments, R 9 is —Cl. In some embodiments, R 9 is —Br. In some embodiments, R 9 is —I.
  • R 7 and R 8 are each independently hydrogen or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • R 9 is hydrogen, halogen, or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • R 7 , R 8 and R 9 are each independently hydrogen or C 1 -C 8 alkyl optionally substituted with 1-3 groups independently selected from hydroxyl, thiol and halogen.
  • n is an integer from 2-7 (i.e. 2, 3, 4, 5, 6, or 7). In some embodiments n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7.
  • m is an integer from 1-4 (i.e. 1, 2, 3, or 4). In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.
  • R 1 and R 2 together with the atoms to which they are attached form a heterocycle
  • X and Y are each independently hydrogen, halogen, —O—, —S—, —NR A —, or —O(P ⁇ O)—OR A (—OR′), wherein R A is hydrogen or alkyl
  • R′, R 3 and R 4 are each independently absent, hydrogen, alkyl, —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 ) (CH 2 ) n (NH)(C ⁇ NH)—NH 2 , —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • R′, R 3 , and R 4 is —(C ⁇ O)-alkyl, —(C ⁇ O)CHR 7 (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH 2 ), —(C ⁇ O)CH(NH 2 )(CH 2 ) n (NH 2 ), —(C ⁇ O)(CH 2 ) n (NH)(C ⁇ NH)—NH 2 or
  • provided herein is one or more compounds selected from Table 1.
  • provided herein is one or more pharmaceutically acceptable salts of a compound selected from Table 1.
  • provided herein is one or more compounds selected from Table 2.
  • provided herein is one or more pharmaceutically acceptable salts of a compound selected from Table 2.
  • X and Y are hydrogen and R 3 and R 4 are absent.
  • X is hydrogen
  • R 3 is absent
  • Y is O
  • R 4 is hydrogen
  • X is hydrogen
  • R 3 is absent
  • Y is O
  • R 4 is Me
  • X is hydrogen
  • R 3 is absent
  • Y is O
  • R 4 is Ac.
  • X is O
  • R 3 is hydrogen
  • Y is hydrogen
  • R 4 is absent.
  • X is O
  • R 3 is Me
  • Y is hydrogen
  • R 4 is absent.
  • X is O
  • R 3 is Ac
  • Y is hydrogen
  • R 4 is absent.
  • provided herein is one or more compounds selected from Table 3.
  • provided herein is one or more pharmaceutically acceptable salts of a compound selected from Table 3.
  • R 3 is absent, X is hydrogen, R 4 is absent, and Y is hydrogen.
  • R 3 is absent, X is hydrogen, R 4 is hydrogen, and Y is —O—.
  • R 3 is absent, X is hydrogen, R 4 is alkyl, and Y is —O—.
  • R 3 is hydrogen
  • X is —O—
  • R 4 is absent hydrogen
  • Y is hydrogen
  • R 3 is alkyl
  • X is —O—
  • R 4 is absent hydrogen
  • Y is hydrogen
  • R 3 is absent, X is hydrogen, R 4 is absent, Y is —O(P ⁇ O)(OR A )(OR′), R A is hydrogen or alkyl, and R′ is hydrogen or alkyl.
  • R 3 is absent, X is hydrogen, R 4 is absent, and Y is —O(P ⁇ O)(OH)(OH).
  • R 3 is absent, X is —O(P ⁇ O)(OR A )(OR′), R A is hydrogen or alkyl, R′ is hydrogen or alkyl, R 4 is absent, and Y is hydrogen.
  • R 3 is absent, X is —O(P ⁇ O)(OH)(OH), R 4 is absent, and Y is hydrogen.
  • provided herein is one or more compounds selected from Table 4.
  • provided herein is one or more pharmaceutically acceptable salts of a compound selected from Table 4.
  • a pharmaceutical composition comprises a therapeutically effective amounts of one or more compounds of the present disclosure (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, further comprise a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent.
  • suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions.
  • suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.
  • the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques.
  • Intraarterial and intravenous injection as used herein includes administration through catheters.
  • the present disclosure provides methods of treating or preventing neurological disorders in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • the neurological disorder is a mood disorder.
  • the mood disorder is clinical depression, postnatal depression or postpartum depression, perinatal depression, atypical depression, melancholic depression, psychotic major depression, cationic depression, seasonal affective disorder, dysthymia, double depression, depressive personality disorder, recurrent brief depression, major depressive disorder, minor depressive disorder, bipolar disorder or manic depressive disorder, depression caused by chronic medical conditions, treatment-resistant depression, refractory depression, suicidality, suicidal ideation, or suicidal behavior.
  • the method described herein provides therapeutic effect to a subject suffering from depression (e.g., moderate or severe depression).
  • the mood disorder is associated with neuroendocrine diseases and disorders, neurodegenerative diseases and disorders (e.g., epilepsy), movement disorders, tremor (e.g., Parkinson's Disease), or women's health disorders or conditions.
  • the mood disorder is depression.
  • the mood disorder is treatment-resistant depression or major depressive disorder.
  • the mood disorder is major depressive disorder.
  • the mood disorder is treatment-resistant depression.
  • the present disclosure provides methods of treating or preventing PTSD, mood disorders, general anxiety disorder, addictive disorders, and/or drug dependence in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • the present disclosure provides methods of treating or preventing PTSD in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • the methods include treating PTSD through induction and maintenance therapy by administering a compound disclosed herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • the compounds of the present disclosure are used for induction and maintenance therapy to treat PTSD with an improved safety profile when compared to treatment with the entactogenic, oneirophrenic or psychedelic compound (e.g., dimethyltryptamine or related compound, psilocybin, or MDMA) alone.
  • the entactogenic, oneirophrenic or psychedelic compound e.g., dimethyltryptamine or related compound, psilocybin, or MDMA
  • the present disclosure provides methods of treating or preventing behavioral or mood disorders in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • a pharmaceutical composition thereof e.g., a pharmaceutical composition thereof.
  • the behavioral or mood disorder includes anxiety, such as social anxiety in autistic subjects (e.g., autistic adults) and anxiety related to life-threatening illnesses.
  • the behavioral or mood disorder includes stress (where moderation thereof is measured, e.g., by effects on amygdala responses).
  • the anxiety disorder is panic disorder, obsessive-compulsive disorder, and/or general anxiety disorder.
  • the subject suffers from a lack of motivation, attention, lack of accuracy in memory recall, speed of response, perseveration, and/or cognitive engagement.
  • Further examples include depression (e.g., MDD or TRD), attention disorders, disorders of executive function and/or cognitive engagement, obsessive compulsive disorder, bipolar disorder, panic disorder, phobia, schizophrenia, psychopathy, antisocial personality disorder and/or neurocognitive disorders.
  • the present disclosure provides methods for treating an addictive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • the addictive disorder is alcohol abuse, substance abuse, smoking, obesity, or mixtures thereof.
  • the disorder is an eating disorder (e.g., anorexia nervosa, bulimia, nervosa, binge eating disorder, etc.) or an auditory disorder.
  • the present disclosure provides methods for treating an impulsive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • the impulsive disorder is attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), Tourette's syndrome, autism, or combinations thereof.
  • the present disclosure provides methods for treating a compulsive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • the compulsive disorder is obsessive compulsive disorder (OCD), gambling, aberrant sexual behavior, or combinations thereof.
  • the present disclosure provides methods for treating a personality disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • a compound disclosed herein e.g., a compound of Formulas (I)-(X) or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof
  • the personality disorder is conduct disorder, antisocial personality, aggressive behavior, or combinations thereof to the subject.
  • reaction products can be purified by known methods including silica gel chromatography using various organic solvents such as hexane, dichloromethane, ethyl acetate, methanol and the like or preparative reverse phase high pressure liquid chromatography.
  • Preparation of compounds can involve the protection and deprotection of various chemical groups.
  • the need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art.
  • the chemistry of protecting groups can be found, for example, in Greene and Wuts, Protective Groups in Organic Synthesis, 44th. Ed., Wiley & Sons, 2006, as well as in Jerry March, Advanced Organic Chemistry, 4 th edition, John Wiley & Sons, publisher, New York, 1992 which are incorporated herein by reference in their entirety.
  • 2-(1H-indol-3-yl)-N,N-dimethylethan-1-amine can be coupled with a carboxylic acid of Formula (A) where PG 1 is a protecting group (such as Boc) under amide coupling conditions (e.g., in the presence of 1,1′-carbonyldiimidazole (CDI), dimethylaminopyridine (DMAP) and a strong base, such as sodium hydride), followed by deprotection of the protecting group PG 1 (e.g., using TFA) to provide compounds of Formula (I-a).
  • PG 1 is a protecting group (such as Boc)
  • amide coupling conditions e.g., in the presence of 1,1′-carbonyldiimidazole (CDI), dimethylaminopyridine (DMAP) and a strong base, such as sodium hydride
  • 2-(1H-indol-3-yl)-N-methylethan-1-amine can be reacted with a carboxylic acid of Formula (A) under amide coupling conditions (e.g., in the presence of CDI, DMAP and a base, such as a tertiary amine base like triethylamine) where PG 1 is a protecting group (such as Boc) followed by deprotection of the protecting group PG 1 (e.g., using TFA) to provide compounds of Formula (I-b).
  • amide coupling conditions e.g., in the presence of CDI, DMAP and a base, such as a tertiary amine base like triethylamine
  • PG 1 is a protecting group (such as Boc) followed by deprotection of the protecting group PG 1 (e.g., using TFA) to provide compounds of Formula (I-b).
  • 3-(2-(dimethylamino)ethyl)-1H-indol-4-ol can be converted into 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl dihydrogen phosphate in the presence of POCl 3 .
  • 3-(2-(dimethylamino)ethyl)-1H-indol-4-yl dihydrogen phosphate can be reacted with a carboxylic acid of Formula (B) in the presence of CDI and a tertiary amine such as triethylamine to form a compound of Formula (I-c).
  • Compounds of Formula (I-c) can be deprotected e.g., with TFA to provide compounds of Formula (I-d).
  • compound 1-2-7 was prepared from 100 mg of 1-2 and 270.2 mg of piperidin-4-ylacetic acid. 7.8 mg (4%) of 1-2-7 was obtained as a white solid. MS m/z [M+H] + (ESI): 287.10.
  • compound 1-2-8 was prepared from 100 mg of 1-2 and 270.2 mg of methyl isonipecotate. 26.1 mg (14%) of 1-2-8 was obtained as a brown solid. MS m/z [M+H] + (ESI): 287.05.
  • compound 1-2-12 was prepared from 100 mg of 1-2 and 243.8 mg of methyl 3-pyrrolidinecarboxylate. 34.1 mg (20%) of 1-2-12 was obtained as a brown solid. MS m/z [M+H] + (ESI): 273.05.
  • the crude product was purified by Prep-HPLC for 2 times with the following condition: Column: X Select CSH Fluoro Phenyl, 30*150 mm, 5 ⁇ m; Mobile Phase A: Water (0.05% HCl), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 28% B to 58% B in 8 min, 58% B; Wavelength: 254 nm; 9.0 mg of 4-1-2 was obtained as a light brown solid. Combined the other batches, 26 mg of 4-1-2 was obtained. MS m/z [M+H] + (ESI): 347.25.
  • the resulting mixture was dissolved in N,N-dimethylformamide (1.0 mL), added entanoic acid (30.0 mg, 0.15 mmol, 1.0 equiv), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (56.3 mg, 0.29 mmol, 2.0 equiv) and 4-dimethylaminopyridine (9.0 mg, 0.07 mmol, 0.5 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 16 h at room temperature. The reaction was diluted with ethyl acetate (3 ⁇ 10 mL), washed with water (3 ⁇ 10 mL).
  • DMT N,N-dimethyltryptamine
  • Prodrug 3-1-4, 4-1-2 and 4-1-4 was supposed to be stable in formulation and should release the parent compound in vivo.
  • VLS-03-10 Parent in PBS pH 6.5, SGF with and without pepsin Peak Area of MRM: 188.7/144.0 VLS-03-10 Compound Analyte Incubation standard 0 min 30 min 60 min 120 min 240 min VLS-03-10 VLS-03-10 Parent PBS (pH 6.5) 4.34E+03 5.32E+03 4.68E+03 5.00E+03 4.72E+03 4.95E+03 VLS-03-10 VLS-03-10 Parent SGF with pepsin 4.05E+03 5.13E+03 5.10E+03 5.25E+03 5.32E+03 5.28E+03 VLS-03-10 VLS-03-10 Parent SGF without pepsin 3.46E+03 5.29E+03 4.98E+03 4.66E+03 4.93E+03 4.61E+03
  • VLS-03-15 Parent in PBS pH 6.5, SGF with and without pepsin Peak Area of MRM: 205.0/159.8 VLS-03-15 Compound Analyte Incubation standard 0 min 30 min 60 min 120 min 240 min VLS-03-15 VLS-03-15 Parent PBS (pH 6.5) 6.74E+05 6.56E+05 6.55E+05 6.28E+05 5.86E+05 5.51E+05 VLS-03-15 VLS-03-15 Parent SGF with pepsin 6.26E+05 6.75E+05 7.21E+05 7.26E+05 7.14E+05 7.15E+05 VLS-03-15 VLS-03-15 Parent SGF without pepsin 6.10E+05 7.05E+05 6.94E+05 6.55E+05 7.09E+05 6.96E+05
  • 6-1-2 was synthesized, as a novel prodrug strategy for improving the water solubility of tertiary amine-containing drugs. And tertiary amine DMT was converted in two step reaction to a very polar, N-Phosphonooxymethyl Prodrug 6-1-3.
  • the prodrug 6-1-2 releases the parent DMT in vivo through a two-step bio-reversion process.
  • the rate determining first step is via an enzymatic process, where prodrug bio-reversion involves a phosphatase-catalyzed dephosphorylation to give the resultant hydroxymethyl quaternary ammonium intermediate and inorganic phosphate.
  • the second step involves conversion of hydroxymethyl quaternary ammonium intermediate chemically to DMT and formaldehyde at physiological pH.
  • 6-1-2 was synthesized, from commercially available in 3 simple steps.
  • prodrug 6-1-2 Chemical stability of prodrug 6-1-2 (VLS-02-23) was evaluated and the results enumerated in Tables 10-11. PK studies of prodrug 6-1-2 and metabolite (VLS-02-23-10) in mice were also conducted and both plasma exposure and brain exposure were analyzed as shown FIGS. 1 - 2 , respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US17/836,984 2021-06-09 2022-06-09 Novel prodrugs and conjugates of dimethyltryptamine Abandoned US20230041584A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/836,984 US20230041584A1 (en) 2021-06-09 2022-06-09 Novel prodrugs and conjugates of dimethyltryptamine
US17/889,013 US11643391B2 (en) 2021-06-09 2022-08-16 Prodrugs and conjugates of dimethyltryptamine
US18/299,347 US12065405B2 (en) 2021-06-09 2023-04-12 Prodrugs and conjugates of dimethyltryptamine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208874P 2021-06-09 2021-06-09
US202163229879P 2021-08-05 2021-08-05
US17/836,984 US20230041584A1 (en) 2021-06-09 2022-06-09 Novel prodrugs and conjugates of dimethyltryptamine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/889,013 Continuation US11643391B2 (en) 2021-06-09 2022-08-16 Prodrugs and conjugates of dimethyltryptamine

Publications (1)

Publication Number Publication Date
US20230041584A1 true US20230041584A1 (en) 2023-02-09

Family

ID=84425491

Family Applications (3)

Application Number Title Priority Date Filing Date
US17/836,984 Abandoned US20230041584A1 (en) 2021-06-09 2022-06-09 Novel prodrugs and conjugates of dimethyltryptamine
US17/889,013 Active US11643391B2 (en) 2021-06-09 2022-08-16 Prodrugs and conjugates of dimethyltryptamine
US18/299,347 Active US12065405B2 (en) 2021-06-09 2023-04-12 Prodrugs and conjugates of dimethyltryptamine

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/889,013 Active US11643391B2 (en) 2021-06-09 2022-08-16 Prodrugs and conjugates of dimethyltryptamine
US18/299,347 Active US12065405B2 (en) 2021-06-09 2023-04-12 Prodrugs and conjugates of dimethyltryptamine

Country Status (10)

Country Link
US (3) US20230041584A1 (https=)
EP (1) EP4352043A4 (https=)
JP (1) JP2024522174A (https=)
KR (1) KR20240019152A (https=)
AU (1) AU2022287974A1 (https=)
CA (1) CA3221823A1 (https=)
CL (1) CL2023003652A1 (https=)
IL (1) IL309210A (https=)
MX (1) MX2023014620A (https=)
WO (1) WO2022261383A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230227407A1 (en) * 2021-12-30 2023-07-20 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
US12065405B2 (en) 2021-06-09 2024-08-20 Atai Therapeutics, Inc. Prodrugs and conjugates of dimethyltryptamine
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
US12396982B2 (en) 2020-05-08 2025-08-26 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022309017A1 (en) * 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
JP2024534801A (ja) * 2021-08-20 2024-09-26 テラン バイオサイエンシズ インコーポレイテッド サイロシンのプロドラッグ及び誘導体ならびにその使用
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
WO2024130140A2 (en) * 2022-12-15 2024-06-20 Atai Therapeutics, Inc. Prodrugs of dimethyltryptamine and derivatives thereof
EP4704833A2 (en) * 2023-04-27 2026-03-11 ATAI Therapeutics, Inc. Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
CN116421600B (zh) * 2023-05-29 2024-08-23 重庆医科大学 色醇在制备治疗焦虑的药物中的应用
TW202525777A (zh) * 2023-08-25 2025-07-01 英商康派斯開拓者公司 ３－（２－（二甲基胺基）乙基）－１ｈ－吲哚－４－基衍生物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1164828A (en) 1965-10-23 1969-09-24 Robins Co Inc A H 3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
JP3361836B2 (ja) 1991-07-04 2003-01-07 三共株式会社 アミノ酸誘導体
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
DE69411143T2 (de) * 1993-09-01 1998-10-22 Allelix Biopharma Tryptamin analoge mit 5-ht1d selektivität
US6025374A (en) 1994-12-06 2000-02-15 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
ID28302A (id) 1999-01-14 2001-05-10 Teijin Ltd Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20050245594A1 (en) 2001-06-29 2005-11-03 Sutter Diane E Dermal delivery of anti-pain agents and methods useful thereof
WO2003026559A2 (en) 2001-09-28 2003-04-03 Kurve Technology, Inc Nasal nebulizer
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
CN102702065A (zh) * 2003-12-30 2012-10-03 什诺波特有限公司 酰氧基烃基氨基甲酸酯前药及其中间体的合成
CA2562783A1 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2006099416A1 (en) 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
US20080318957A1 (en) 2007-05-11 2008-12-25 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
WO2011041870A1 (en) 2009-10-07 2011-04-14 Nitrogenix Inc. Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
EP2771341A4 (en) 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
CN104508126B (zh) 2012-03-23 2017-06-30 科德克希思公司 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
CN110177581B (zh) 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
MX2020009254A (es) 2018-03-08 2021-01-15 New Atlas Biotechnologies Llc Procesos para la produccion de triptaminas.
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
AU2019324952B2 (en) 2018-08-22 2024-10-24 University Of Technology Sydney NBOMe test
HUE069534T2 (hu) 2019-02-22 2025-03-28 Gh Res Ireland Limited 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
AU2020386445B2 (en) 2019-11-19 2025-12-18 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
CA3166785A1 (en) 2020-02-05 2021-08-12 Yale University Psychedelic treatment for headache disorders
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
IL301066A (en) 2020-09-04 2023-05-01 Gilgamesh Pharmaceuticals Inc Azetidinyl tryptamines and methods for the treatment of psychiatric disorders
AU2021343525A1 (en) 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022082058A1 (en) 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
JP2024517738A (ja) 2021-04-26 2024-04-23 アタイ セラピューティクス， インコーポレイテッド 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法
JP2024517194A (ja) 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
WO2022235514A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
CA3218110A1 (en) 2021-05-25 2022-12-01 Majed Fawaz New n,n-dimethyltryptamine salts and crystalline salt forms
BR112023024688A2 (pt) 2021-05-26 2024-02-15 Mindset Pharma Inc Combinação de halucinógeno-ácido graxo
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
JP2024533291A (ja) 2021-09-08 2024-09-12 サイビン アイアールエル リミテッド 併用薬物療法
US20230099972A1 (en) 2021-09-30 2023-03-30 ATAI Life Sciences AG Compositions and methods for treating headaches
US20230310374A1 (en) 2021-09-30 2023-10-05 ATAI Life Sciences AG Compositions and methods for treating headache or facial pain
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396982B2 (en) 2020-05-08 2025-08-26 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12472163B2 (en) 2020-05-08 2025-11-18 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
US12065405B2 (en) 2021-06-09 2024-08-20 Atai Therapeutics, Inc. Prodrugs and conjugates of dimethyltryptamine
US20230227407A1 (en) * 2021-12-30 2023-07-20 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
US12012381B2 (en) * 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
US12606525B2 (en) 2021-12-30 2026-04-21 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs

Also Published As

Publication number Publication date
WO2022261383A1 (en) 2022-12-15
US20230066720A1 (en) 2023-03-02
KR20240019152A (ko) 2024-02-14
EP4352043A4 (en) 2025-06-25
MX2023014620A (es) 2024-01-30
JP2024522174A (ja) 2024-06-11
CA3221823A1 (en) 2022-12-15
CL2023003652A1 (es) 2024-05-17
US11643391B2 (en) 2023-05-09
IL309210A (en) 2024-02-01
US12065405B2 (en) 2024-08-20
EP4352043A1 (en) 2024-04-17
AU2022287974A1 (en) 2024-01-04
US20230357146A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US11643391B2 (en) Prodrugs and conjugates of dimethyltryptamine
US11845736B2 (en) Prodrugs of MDMA, MDA, and derivatives thereof
US20240287107A1 (en) Prodrugs of dimethyltryptamine and derivatives thereof
US20240317724A1 (en) 3,4-methylenedioxymethamphetamine and related psychedelics and uses thereof
US12454516B2 (en) Nitric oxide releasing prodrugs of MDA and MDMA
DE3718317A1 (de) Substituierte basische 2-aminotetraline
CN107530350A (zh) 细胞坏死抑制剂及相关方法
WO2025019800A1 (en) Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same
BR112015022849B1 (pt) Sais de adição de base de nitroxolina, usos e processo para preparação dos mesmos, bem como seu cristal, composição farmacêutica e processo para preparação da mesma
US20240425470A1 (en) Substituted benzofuran propyl amine modulators of monoaminergic transporters
EP4259148A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
CN114599362B (zh) 苯基喹啉酮类和黄酮类衍生物在制备治疗神经病理性疼痛的药物中的用途
CN117500787A (zh) 二甲基色胺的新型前药和缀合物
WO2024145464A2 (en) Ibogaine and noribogaine prodrugs and methods of use
JP7174700B2 (ja) ロイコトリエンａ４ヒドロラーゼの阻害剤としてのモノアミン及びモノアミン誘導体
WO2022271969A2 (en) Prodrugs of acyl carnitines
CA3045887A1 (en) Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
ES2286240T3 (es) Derivados sustituidos de propano-1,3-diamina y su utilizacion farmaceutoca de los mismos.
WO2024145462A1 (en) Ibogaine and noribogaine analogs and methods of use
CA3224835A1 (en) Novel psilocin prodrug compounds and methods of synthesizing the same
US20250197395A1 (en) Ibogaine and noribogaine analogs and uses thereof
WO2025042956A1 (en) Pde 7 modulator compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: JMD PHARMA CREATIVITY, LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERNI, ROBERT B.;REEL/FRAME:061892/0104

Effective date: 20221115

Owner name: ATAI LIFE SCIENCES AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHORT, GLENN;RAO, SRINIVAS G.;KHAN, TANWEER A.;REEL/FRAME:061891/0665

Effective date: 20221115

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: ATAI LIFE SCIENCES US, INC., GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JMD PHARMA CREATIVITY, LLC;REEL/FRAME:063778/0289

Effective date: 20230421

AS Assignment

Owner name: ATAI LIFE SCIENCES AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATAI LIFE SCIENCES US, INC.;REEL/FRAME:064175/0571

Effective date: 20230421

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: VIRIDIA LIFE SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATAI LIFE SCIENCES AG;REEL/FRAME:065345/0430

Effective date: 20230914

AS Assignment

Owner name: ATAI THERAPEUTICS, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:VIRIDIA LIFE SCIENCES, INC.;REEL/FRAME:065416/0595

Effective date: 20230818